All articles
Does Semaglutide Affect Fertility or Pregnancy?
Reading time:
15 min
Women's Health
Get expert guidance and a personalized care plan designed around you.
What to Do If You Get Pregnant While Taking Semaglutide
Despite best intentions and precautions, unintended pregnancies happen. If you discover you are pregnant while taking semaglutide, knowing what to do reduces anxiety and ensures appropriate medical care.
First, stop taking the medication immediately once you know you are pregnant. Do not take any additional doses. The goal is minimizing fetal exposure by stopping as soon as pregnancy is confirmed.
Second, contact your healthcare provider right away. They need to know about the pregnancy and the medication exposure. Your provider can advise you on next steps, refer you for appropriate prenatal care if needed, and document the exposure for monitoring purposes.
Third, try not to panic. While semaglutide is contraindicated in pregnancy, brief early exposure (particularly before you knew you were pregnant) does not automatically mean something is wrong. Many medications are contraindicated in pregnancy out of abundant caution rather than confirmed harm. The lack of human safety data creates uncertainty, but uncertainty is not the same as known danger.
Your prenatal care provider might recommend additional monitoring during pregnancy, though there are no specific tests that detect semaglutide-related effects. Standard prenatal care including ultrasounds and routine testing will monitor fetal development. Most pregnancies with early medication exposures that should not have occurred still result in healthy babies. This does not mean the exposure was risk-free, but it means outcomes are often good despite imperfect circumstances.
If you were actively trying to conceive while still taking semaglutide (against medical advice), the situation is similar. Stop the medication immediately, contact your providers, and proceed with appropriate prenatal care and monitoring.
Some women taking semaglutide for weight loss or diabetes management find their menstrual cycles become more regular and predictable as they lose weight, which can make previously irregular cycles suddenly more fertile. This creates situations where pregnancy occurs unexpectedly because fertility improved on medication. Using reliable contraception while taking semaglutide prevents this scenario if pregnancy is not desired.
Male Fertility and Semaglutide
Most discussion about semaglutide and reproduction focuses on women, but men planning to father children also have questions about whether the medication affects fertility or poses risks to future offspring.
Current evidence suggests semaglutide does not significantly affect male fertility. Animal studies have not shown effects on sperm production, sperm quality, or male reproductive organs at therapeutic doses. The medication does not appear in semen at levels that would affect a partner or developing pregnancy.
Unlike the recommendations for women, men do not need to stop semaglutide before attempting to conceive. The medication's contraindication applies to pregnancy itself (the pregnant person taking the medication), not to the reproductive contributions of a partner.
However, obesity in men is associated with reduced fertility through multiple mechanisms including lower testosterone levels, erectile dysfunction, reduced sperm quality and motility, and increased DNA fragmentation in sperm. Weight loss in obese men generally improves these parameters, potentially improving fertility.
If you are a man taking semaglutide for weight loss and planning to father children, the weight loss itself is likely beneficial for fertility. There is no need to stop the medication for a washout period before attempting conception with your partner. You can continue treatment throughout your partner's pregnancy without concern.
If you have specific fertility concerns or are undergoing fertility treatment, discuss your semaglutide use with your fertility specialist. While general evidence suggests no problems with male fertility on GLP-1 medications, individual situations might benefit from specialized guidance.
Breastfeeding Considerations
The guidance for semaglutide during breastfeeding is less definitive than the pregnancy contraindication, reflecting a different risk-benefit calculation and significant gaps in knowledge.
We do not know whether semaglutide passes into human breast milk. Animal studies suggest minimal to no presence in milk, but animal lactation does not perfectly predict human lactation. Without human data, we cannot definitively say the medication does or does not enter breast milk, and if it does, at what concentrations.
The prescribing information lists breastfeeding as a time to avoid semaglutide or to make a decision between breastfeeding and taking medication based on the importance of the medication to the mother and potential unknown risks to the infant. This reflects the uncertainty. The medication might be safe during breastfeeding, but we do not have evidence to confidently state that it is.
Many providers recommend against semaglutide during breastfeeding out of caution, particularly in the early months when breastfeeding is being established and infant exposure would be highest. However, some providers might support use of GLP-1 medications during breastfeeding in specific situations, particularly if the mother has diabetes requiring management and other options are limited.
If you choose not to breastfeed, you can resume semaglutide immediately after giving birth. There is no need for a waiting period. For women who do breastfeed, the decision about when to start or restart semaglutide involves weighing the benefits of continued breastfeeding against the benefits of weight loss or diabetes management and the unknown risks of medication exposure through breast milk.
This decision should be made collaboratively with your healthcare provider based on your individual circumstances, health needs, and infant feeding plans. There is no single right answer that applies to everyone.
Planning Pregnancy While on Semaglutide
If you are currently taking semaglutide and planning pregnancy in the future, a structured approach helps you achieve your health goals while safely timing medication discontinuation.
Start by establishing your timeline. When are you hoping to conceive? If pregnancy is desired within the next six months, you will need to plan for stopping medication soon. If pregnancy is a year or more away, you have more time to work on weight loss goals before discontinuing.
Discuss your pregnancy plans with your provider early rather than waiting until you are ready to stop medication. They can help you develop a comprehensive plan that addresses weight loss goals, optimal timing for medication discontinuation, strategies for maintaining weight loss after stopping, overall health optimization for pregnancy, and any other medical considerations for conception.
Consider whether you have reached your weight loss goals or whether you are still in active weight loss phase. If you are close to your goal weight, stopping medication after achieving and stabilizing at goal weight might make sense. If you are still significantly above goal weight, you might prioritize continued weight loss for a defined period before stopping for conception attempts.
Weight loss before pregnancy offers health benefits for both mother and baby. Achieving a healthier weight before conception reduces risks of gestational diabetes, preeclampsia, pregnancy loss, cesarean delivery, and various complications. The time you spend on weight loss medication before pregnancy is an investment in a healthier pregnancy, even though you need to discontinue the medication before conceiving.
If you have conditions like PCOS or irregular cycles that improved on semaglutide due to weight loss, work with your provider on strategies to maintain this improvement after stopping medication. Often the metabolic improvements from weight loss persist even after medication discontinuation, at least in the short term.
Consider working with a registered dietitian during your time on medication and particularly during the transition off medication before conception. Building sustainable eating patterns while on medication makes weight maintenance easier after stopping. At Mochi Health, all patients have access to registered dietitian nutritionists who can help you develop strategies for maintaining your weight loss as you transition off medication for pregnancy planning.
Contraception While Taking Semaglutide
If you are sexually active, not planning pregnancy, and taking semaglutide, reliable contraception is important for several reasons.
Weight loss itself can increase fertility, particularly for women who experienced weight-related ovulatory dysfunction. Women who previously did not get pregnant due to weight-related infertility might find their fertility restored as they lose weight, leading to unintended pregnancy if not using contraception.
Additionally, semaglutide can affect absorption of oral medications during the first few weeks of treatment or after dose increases due to nausea, vomiting, or changes in gastric emptying. While specific studies on oral contraceptive absorption with GLP-1 medications are limited, some providers recommend backup contraception during the first month of treatment and for a week after dose increases if using oral birth control as your primary method.
Long-acting reversible contraceptive methods like IUDs or implants are not affected by GLP-1 medications and provide reliable pregnancy prevention without concerns about absorption. If pregnancy is not desired while taking semaglutide, discussing contraceptive options with your provider ensures appropriate protection.
If unplanned pregnancy occurs despite contraception, follow the guidance about stopping medication immediately and contacting your providers for appropriate prenatal care.
Weight Loss, Pregnancy Planning, and Metabolic Health
Beyond the direct effects of medication, the metabolic improvements from weight loss create a healthier foundation for pregnancy.
Losing excess weight before pregnancy offers numerous benefits. It improves insulin sensitivity and reduces risk of gestational diabetes, lowers blood pressure and reduces preeclampsia risk, improves lipid profiles, reduces inflammation, enhances cardiovascular health, and decreases risks of pregnancy complications.
For women with type 2 diabetes or prediabetes, weight loss often significantly improves glycemic control. Achieving better blood sugar control before pregnancy is crucial, as uncontrolled diabetes at conception and during early pregnancy dramatically increases risks of birth defects and pregnancy complications.
If you want to assess your metabolic health improvements before pregnancy, you can discuss lab testing with your provider. While labs are not required for GLP-1 treatment, some patients and providers find it helpful to check markers like hemoglobin A1c (for blood sugar control), lipid panel, thyroid function, and other relevant tests before stopping medication for conception attempts. This provides baseline information about your metabolic health and can inform any adjustments needed as you transition off medication. The decision about lab testing should be made collaboratively based on your individual health needs and goals.
The time you spend on weight loss medication before pregnancy is not wasted even though you need to stop the medication itself. You are achieving metabolic improvements that persist beyond medication discontinuation and create a healthier environment for conception and pregnancy.
Managing Weight After Stopping for Pregnancy
One of the biggest concerns about stopping semaglutide for pregnancy is the risk of weight regain. Research shows that most people regain significant weight when stopping GLP-1 medications if they do not maintain intensive lifestyle modifications.
Strategies for minimizing regain during the washout period and pregnancy planning include continuing the healthy eating patterns you developed while on medication, maintaining regular physical activity appropriate for your fitness level, working with a registered dietitian for ongoing nutrition support, getting adequate sleep and managing stress, and building a strong support system.
Some weight regain is common and should not derail pregnancy plans. The goal is not maintaining every pound lost, but rather preserving as much of the metabolic improvement as possible while transitioning to pregnancy at a healthier baseline than where you started.
Pregnancy itself is not a time to focus on weight loss. Normal pregnancy involves weight gain. The goal is entering pregnancy at a healthier weight than before, even if some regain has occurred after stopping medication.
At Mochi Health, we understand that weight loss journeys intersect with life plans including family planning. Our providers offer personalized guidance on timing medication discontinuation for pregnancy, strategies for maintaining weight loss during washout periods, and comprehensive support that extends beyond just medication management. Our registered dietitian nutritionists can help you develop sustainable eating patterns that support weight maintenance when you transition off medication for pregnancy.
We also offer a comprehensive range of medications to support various aspects of your health beyond weight loss. If you are planning pregnancy and working on optimizing your overall health, you can explore treatment options at https://joinmochi.com/medications.
The Bigger Picture: Reproductive Health and Weight Management
The intersection of weight management medications and reproductive planning highlights the complexity of healthcare decisions that extend beyond any single medical issue.
Obesity is associated with reduced fertility, increased pregnancy complications, higher risks for both mother and baby, and longer-term health consequences. Medications like semaglutide offer effective tools for achieving healthier weight. But pregnancy represents a situation where this particular tool needs to be set aside, even though the underlying condition (obesity) would benefit from continued treatment.
This creates tension between short-term goals (continuing medication for ongoing weight loss) and longer-term goals (achieving pregnancy in a healthy manner). Navigating this tension requires planning, clear communication with providers, realistic expectations about weight management during pregnancy planning, and commitment to maintaining lifestyle changes when medication is discontinued.
The good news is that the metabolic improvements from weight loss often persist, at least partially, after stopping medication. The time you invest in weight loss before pregnancy is not lost just because you stop medication. You have achieved meaningful health improvements that benefit both you and your future pregnancy.
Check Your Eligibility
If you want to learn whether GLP-1 treatment is right for you and receive personalized guidance from providers who understand the complexities of reproductive planning alongside weight management, you can start by completing Mochi's eligibility questionnaire. It takes just a few minutes and helps our clinical team understand your goals and health needs. Check your eligibility.
References:
Eli Lilly and Company. (2023). Zepbound (tirzepatide) injection prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
Grieger, J. A., Hutchesson, M. J., Cooray, S. D., Bahri Khomami, M., Zaman, S., Segan, L., Teede, H., Harrison, C. L., & Moran, L. J. (2021). A review of maternal overweight and obesity and its impact on cardiometabolic outcomes during pregnancy and postpartum. Therapeutic Advances in Reproductive Health, 15, 1-22. https://doi.org/10.1177/2633494120986544
Legro, R. S., Dodson, W. C., Kris-Etherton, P. M., Kunselman, A. R., Stetter, C. M., Williams, N. I., Gnatuk, C. L., Estes, S. J., Fleming, J., Allison, K. C., Sarwer, D. B., Coutifaris, C., & Dokras, A. (2015). Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 100(11), 4048-4058. https://doi.org/10.1210/jc.2015-2778
Novo Nordisk. (2023). Wegovy (semaglutide) injection prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s006lbl.pdf
Practice Committee of the American Society for Reproductive Medicine. (2015). Obesity and reproduction: A committee opinion. Fertility and Sterility, 104(5), 1116-1126. https://doi.org/10.1016/j.fertnstert.2015.08.018
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. https://doi.org/10.1001/jama.2021.3224
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
This article is for educational purposes only and should not be considered medical advice. Consult with healthcare providers about how semaglutide relates to your individual reproductive planning and pregnancy considerations.
Share this post
Women's Health
More articles
Read next
For iOS & Android
